(Q38445280)

3 September 2017

1 reference

title

Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology (English)

1 reference

3 September 2017

1 reference

irritable bowel syndrome

1 reference

2

1 reference

3 September 2017

1

Nicholas J Talley

1 reference

3 September 2017

Marjorie M Walker

3

1 reference

3 September 2017

publication date

29 April 2015

1 reference

Journal of Gastroenterology

3 September 2017

published in

1 reference

3 September 2017

volume

50

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

601-613

1 reference

Functional gastroduodenal disorders

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Whither dyspepsia? A historical perspective of functional dyspepsia, and concepts of pathogenesis and therapy in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Functional dyspepsia impacts absenteeism and direct and indirect costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Functional gastrointestinal disorders as a public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The impact of functional gastrointestinal disorders on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The irritable bowel syndrome: long-term prognosis and the physician-patient interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Complicated and uncomplicated peptic ulcer disease: altered symptom response to a nutrient challenge linked to gastric motor dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Systematic review with meta-analysis: prompt endoscopy as the initial management strategy for uninvestigated dyspepsia in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Evidence-based clinical practice guidelines for irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Asian consensus on irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Atopy and the gastrointestinal tract--a review of a common association in unexplained gastrointestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Effects of Birth Cohorts on the Irritable Bowel Syndrome Support Early-Life Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Irritable bowel syndrome in twins: genes and environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Therapeutic options for functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Irritable brain caused by irritable bowel? A nationwide analysis for irritable bowel syndrome and risk of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Pathways in gut-brain communication: evidence for distinct gut-to-brain and brain-to-gut syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Consumption of fermented milk product with probiotic modulates brain activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Survival in hostile territory: the microbiota of the stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract--beyond the era of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

High temporal and inter-individual variation detected in the human ileal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The role of the gut microbiota in nutrition and health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A role for the gut microbiota in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Brain-gut microbiome interactions and functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Eradication of Helicobacter pylori for non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Host-bacterial interactions in Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

ABC of the upper gastrointestinal tract: Pathophysiology of duodenal and gastric ulcer and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Helicobacter pylori infection in functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Dysaccommodation of the stomach: therapeutic nirvana?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Fasting and postprandial gastric sensorimotor activity in functional dyspepsia: postprandial distress vs. epigastric pain syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Herbal medicines for the treatment of functional and inflammatory bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Changes in gastrointestinal tract function and structure in functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Immune dysfunction in patients with functional gastrointestinal disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The role of eosinophils and mast cells in intestinal functional disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Randomised controlled trial of mesalazine in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

A 13-nation population survey of upper gastrointestinal symptoms: prevalence of symptoms and socioeconomic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1076-X

21 January 2018

1 reference

12 December 2020

Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations

1 reference

12 December 2020

Impact of psychological stress on irritable bowel syndrome

1 reference

12 December 2020

Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects

1 reference

12 December 2020

Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia

1 reference

12 December 2020

Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric ischaemia and reperfusion.

1 reference

12 December 2020

Stress and gastrointestinal tract. II. Stress and intestinal barrier function

1 reference

12 December 2020

Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts

1 reference

12 December 2020

The slowing of gastric emptying by four strong acids and three weak acids

1 reference

12 December 2020

Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden

1 reference

12 December 2020

Emerging drugs for functional dyspepsia

1 reference

12 December 2020

Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease

1 reference

12 December 2020

Does psychological distress modulate functional gastrointestinal symptoms and health care seeking? A prospective, community cohort study

1 reference

12 December 2020

Gastric acid reduction leads to an alteration in lower intestinal microflora

1 reference

12 December 2020

Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation

1 reference

12 December 2020

Diet as a therapy for irritable bowel syndrome: progress at last

1 reference

12 December 2020

1 reference

12 December 2020

Genome-Wide Association Study Identifies Two Novel Genomic Regions in Irritable Bowel Syndrome

1 reference

12 December 2020

An evidence-based position statement on the management of irritable bowel syndrome

1 reference

12 December 2020

Gastroparesis: separate entity or just a part of dyspepsia?

1 reference

12 December 2020

The epidemiology of irritable bowel syndrome

1 reference

12 December 2020

Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options

1 reference

12 December 2020

Pathophysiology of functional dyspepsia

1 reference

12 December 2020

Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis

1 reference

12 December 2020

Visceral sensitivity perturbation integration in the brain-gut axis in functional digestive disorders.

1 reference

12 December 2020

High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria

1 reference

12 December 2020

Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach.

1 reference

12 December 2020

Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis

1 reference

12 December 2020

10.1007/S00535-015-1076-X

Identifiers

DOI

1 reference

3 September 2017

1 reference